Articles with the topic: clinical-trial

Updates from the EHDN Plenary Meeting 2020

Updates from the EHDN Plenary Meeting 2020

Read our summary of the latest updates from the EHDN Plenary Meeting 2020

Dr Rachel HardingJanuary 08, 2021

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 2

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 2

The 2020 virtual HSG conference HD in Focus continues on Day 2 with a focus on clinical trials and drugs in development.

Dr Leora Fox and Dr Rachel HardingNovember 01, 2020

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 1

Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 1

Read our breakdown of some of the talks and presentations at day 1 of the Huntington Study Group (HSG) 2020 annual conference: HD in focus

Dr Rachel HardingOctober 30, 2020

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

Treatment for neurological disorder could be repurposed for Huntington’s disease patients

While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD. The FDA has granted a special status called Orphan Drug Designation.

Dr Rachel HardingOctober 22, 2020

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

The SIGNAL study did not meet its key clinical goals for #HuntingtonsDisease to slow or improve HD symptoms, but the results are still informative for the HD community and other fields.

Dr Jeff CarrollSeptember 23, 2020

HD Young Adult Study defines the sweet spot: symptom-free with measurable changes

HD Young Adult Study defines the sweet spot: symptom-free with measurable changes

We know that HD-related changes can occur many years before symptom onset, but how early do those changes begin? A team of researchers set out to determine that with a new comprehensive study in pre-manifest HD young adults.

Dr Sarah HernandezMay 27, 2020

What does COVID-19 mean for Huntington’s disease families and HD research?

What does COVID-19 mean for Huntington’s disease families and HD research?

COVID-19 update: what does it mean for HD families, how does it impact HD research, and how has it changed the way science works?

Dr Sarah Hernandez and Professor Ed WildApril 06, 2020

Unpacking Wave's PRECISION-HD2 huntingtin-lowering trial announcement

Unpacking Wave's PRECISION-HD2 huntingtin-lowering trial announcement

Wave Life Sciences announces that its antisense drug WVE-120102 has lowered mutant huntingtin protein in cerebrospinal fluid, but investors seem disappointed. Rather confusing – what do we know for sure?

Dr Jeff CarrollJanuary 03, 2020

Details emerge of first Huntington’s disease gene therapy clinical trial

Details emerge of first Huntington’s disease gene therapy clinical trial

UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein using a ‘single-shot’ virus delivery system.

Dr Anna PfalzerJuly 17, 2019